moxifloxacin has been researched along with sq 109 in 6 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (sq 109) | Trials (sq 109) | Recent Studies (post-2010) (sq 109) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 58 | 3 | 41 |
| Protein | Taxonomy | moxifloxacin (IC50) | sq 109 (IC50) |
|---|---|---|---|
| Geranylgeranyl pyrophosphate synthase | Homo sapiens (human) | 4.5 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 5.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Aarnoutse, RE; Boeree, MJ; Kibiki, GS; Kisanga, ER; van den Boogaard, J | 1 |
| Baulard, AR; Crauste, C; Déprez, B; Flipo, M; Villemagne, B; Willand, N | 1 |
| Kumari, D; Perveen, S; Sharma, R; Singh, K | 1 |
| Cole, ST; Hartkoorn, RC; Lechartier, B | 1 |
| Jeong, BH; Koh, WJ; Kwon, YS | 1 |
| Aarnoutse, R; Boeree, MJ; Charalambous, S; Churchyard, G; Colbers, A; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; Heinrich, N; Henne, S; Hoelscher, M; Hunt, RD; Kibiki, GS; Manyama, C; Mekota, A; Minja, LT; Mpagama, SG; Mtafya, B; Narunsky, K; Ntinginya, NE; Phillips, PPJ; Rehal, S; Reither, K; Sanne, I; Semvua, HH; van Balen, GP; Venter, A; Wallis, RS | 1 |
4 review(s) available for moxifloxacin and sq 109
| Article | Year |
|---|---|
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Mycobacterium tuberculosis; Rifamycins; Tuberculosis | 2009 |
Tuberculosis: the drug development pipeline at a glance.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Humans; Tuberculosis | 2012 |
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin | 2022 |
Tuberculosis: clinical trials and new drug regimens.
Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
1 trial(s) available for moxifloxacin and sq 109
| Article | Year |
|---|---|
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Ethylenediamines; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Pyrazinamide; Rifampin; South Africa; Tanzania; Tuberculosis, Pulmonary | 2017 |
1 other study(ies) available for moxifloxacin and sq 109
| Article | Year |
|---|---|
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins | 2012 |